

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ESSEX BIO-TECHNOLOGY LIMITED

億勝生物科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1061)

ANNOUNCEMENT

DISTRIBUTION AGREEMENT WITH ELEKTRON TECHNOLOGY UK LIMITED

This announcement is made pursuant to Rule 13.09 of the Listing Rules and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

On 27 May 2015, Essex Bio-Pharmacy entered into the Distribution Agreement with Elektron, pursuant to which Elektron appointed Essex Bio-Pharmacy as its exclusive distributor of the Macular Pigment Screener II including spare parts in the PRC.

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

On 27 May 2015, Essex Bio-Pharmacy Limited (“**Essex Bio-Pharmacy**”), an indirect wholly-owned subsidiary of Essex Bio-Technology Limited (the “**Company**”, and together with its subsidiaries referred as the “**Group**”), entered into a distribution agreement (“**Distribution Agreement**”) with Elektron Technology UK Limited (“**Elektron**”), a company incorporated in England and Wales. Elektron is principally engaged in the manufacturing of electronic components.

Pursuant to the Distribution Agreement, Elektron appointed Essex Bio-Pharmacy as its exclusive distributor of Macular Pigment Screener II including spare parts in the People's Republic of China (excluding Taiwan, the Hong Kong Special Administrative Region and the Macau Special Administrative Region) (“**PRC**”).

The Distribution Agreement is for a period of eight years from the date on which Essex Bio-Pharmacy placed the first purchase order with Elektron and may be automatically extended for successive periods of two years each. The Macular Pigment Screener II is a portable screening device that enables early detection of patients at risk of Age-related Macular Degeneration – one of the leading causes of vision loss in people over fifty.

The Group is principally engaged in the manufacturing, selling, marketing and distribution of biopharmaceutical products.

The collaboration with Elektron establishes a milestone of the Group in the ophthalmic medical device market and expands the range of the Group's eye care solutions, which will together benefit the Group in striving for sustainable growth in the ophthalmology arena in the PRC.

By Order of the Board
Essex Bio-Technology Limited
Ngiam Mia Je Patrick
Chairman

Hong Kong, 28 May 2015

Executive directors of the Company as at the date of this announcement are Mr. Ngiam Mia Je Patrick, Mr. Fang Haizhou and Mr. Zhong Sheng. Independent non-executive directors of the Company as at the date of this announcement are Mr. Fung Chi Ying, Mr. Mauffrey Benoit Jean Marie and Ms. Yeow Mee Mooi.